The Experts below are selected from a list of 33 Experts worldwide ranked by ideXlab platform
Michael I. Lindinger - One of the best experts on this subject based on the ideXlab platform.
-
Low quality of evidence for glucosamine-based nutraceuticals in equine joint disease: Review of in vivo studies
Equine veterinary journal, 2009Co-Authors: Wendy Pearson, Michael I. LindingerAbstract:Nutraceuticals are increasingly applied to the management of equine arthritis and joint disease, particularly those based upon glucosamine and chondroitin sulphate. While the first report of using glucosamine in horses appeared more than 25 years ago, it was not until 1992 that isolated studies began to be reported. Since that time, 15 in vivo papers have been published in the equine literature, usually on products already commercially available and often seeking evidence for efficacy. These studies demonstrate an encouraging trend to manufacturers of these products investing in research, but most do not meet a quality standard that provides sufficient confidence in the results reported. This review discusses the entirety of published in vivo research on glucosamine-based nutraceuticals (GBN) for horses, including that on Cosequin, Cortaflex, Synequin, Sasha's EQ, Myristol, chondroitin sulphate, glucosamine sulphate and glucosamine hydrochloride; and considers experimental limitations of this research along with their impact on interpretation of results. A quality score was calculated for each paper according to preset quality criteria. A minimum quality standard of 60% was set as the threshold for confidence in interpretation of results. Of the 15 papers reviewed, only 3 met the minimum quality standard. Experimental limitations of each research paper are discussed. It is concluded that the quality of studies in this area is generally low, prohibiting meaningful interpretation of the reported results. New high quality research on GBN for horses is needed and recommendations for future research are discussed.
Todd Henderson - One of the best experts on this subject based on the ideXlab platform.
-
Development and validation of a photometric titration method for the quantitation of sodium chondroitin sulfate (bovine) in Cosequin DS chewable tablet.
Journal of pharmaceutical and biomedical analysis, 2002Co-Authors: Zhongming Liang, Corrine Bonneville, Terrin Senez, Todd HendersonAbstract:Abstract A photometric titration method was developed and validated to quantitate sodium chondroitin sulfate in raw materials and Cosequin® DS chewable tablet 1 . About 0.1% (w/v) cetylpyridinium chloride was used to titrate sodium chondroitin sulfate with photometric indication at wavelengh 420 nm. The standard curves for sodium chondroitin sulfate showed linearity ( r ≥0.99) over the selected concentration range from 0.6 to 1.4 mg/ml. The chewable tablet was ground to fine powder and extracted with water and the resulting solutions filtered through a 0.45 μm membrane filter. Recovery between 97 and 103%,. The intra- and inter- day precision as indicated by the relative standard deviation (R.S.D.) were not greater than 0.33 and 0.78%, respectively. The method was found to be specific and with excellent linearity, accuracy and precision and is well suited for the quantitation of sodium chondroitin sulfate in raw material and Cosequin® DS chewable tablet.
Todd R. Henderson - One of the best experts on this subject based on the ideXlab platform.
-
Protective effect of the chondroprotective agent Cosequin DS on bovine articular cartilage exposed in vitro to nonsteroidal antiinflammatory agents.
Veterinary therapeutics : research in applied veterinary medicine, 2002Co-Authors: Louis Lippiello, Sung Han, Todd R. HendersonAbstract:Studies were conducted to test the hypothesis that exposure of articular cartilage to a combination of the "chondroprotective" agents glucosamine hydrochloride, low-molecular-weight chondroitin sulfate, and manganese ascorbate (Cosequin DS [CDS], Nutramax Laboratories, Inc.) prevents the potentially adverse effects of NSAIDs on cartilage. Articular cartilage proteoglycan synthesis and degradation were used to monitor in vitro cartilage activity following timed exposure to levels of NSAIDs routinely applied in veterinary medicine. Etodolac exposure for 144 hours induced significant inhibition of cartilage matrix synthesis and increased the rate of matrix breakdown. Addition of CDS reversed both activities. Cartilage metabolism was not affected by exposure to indomethacin and remained responsive to CDS with an increase in synthetic activity. Aspirin significantly stimulated chondrocyte synthetic activity in the presence and absence of CDS. Carprofen at therapeutic levels had a mild (15%) stimulatory effect on cartilage metabolism and reduced matrix breakdown. Addition of CDS significantly accelerated (30%) matrix synthesis. At higher levels carprofen was toxic, reducing cell activity by 80%. The data suggest that CDS may be a useful adjunct therapy for preservation of articular cartilage by reversing the adverse metabolic effects of etodolac and providing accelerated cartilage synthetic activity in the presence of therapeutic levels of carprofen.
Carolyn R. Boyle - One of the best experts on this subject based on the ideXlab platform.
-
Changes to articular cartilage following remote application of radiofrequency energy and with or without Cosequin therapy.
Veterinary and comparative orthopaedics and traumatology : V.C.O.T, 2009Co-Authors: C. L. Horstman, Ron Mclaughlin, Steven H. Elder, Roy R. Pool, R. R. Read, Carolyn R. BoyleAbstract:Objective: To determine the short- and long-term changes in the biomechanical properties and metabolic activity of articular cartilage following the remote application of bipolar radiofrequency (bRF) and monopolar radiofrequency (mRF) energy within the rabbit stifle joint. Methods: The rabbits were randomly assigned to either Group-1 (normal rabbit food), or they were assigned to Group-2 (2% Cosequin® in the diet). Each rabbit underwent bilateral stifle arthroscopy with either bRF or mRF applied to the infrapatellar fat pad for 45 seconds. Cartilage samples were collected at zero, four, and 14 weeks after surgery. Data were analyzed with a mixed model analysis of variance (ANOVA) for chondrocyte death, amount of GAG synthesis, and the equilibrium compressive modulus. Results: A significant increase in histological damage was noted at weeks four and 14 compared to week zero. Most of the chondrocyte death noted with confocal laser microscopy (49 of 56 samples) was noted in the superficial region (outer 25%) of the articular cartilage. GAG synthesis was not significantly different between groups or devices at any time point. A significant difference was not noted in equilibrium compressive modulus throughout the study. Conclusions: Remote application of bRF and mRF energy lead to immediate chondrocyte death. Most of the damage was superficial hence the metabolic activity and biomechanical properties of the extracellular matrix were maintained throughout this study. Treatment with Cosequin did not prevent superficial chondrocyte death caused by the application of radiofrequency (RF) energy with in the joint.
Wendy Pearson - One of the best experts on this subject based on the ideXlab platform.
-
Low quality of evidence for glucosamine-based nutraceuticals in equine joint disease: Review of in vivo studies
Equine veterinary journal, 2009Co-Authors: Wendy Pearson, Michael I. LindingerAbstract:Nutraceuticals are increasingly applied to the management of equine arthritis and joint disease, particularly those based upon glucosamine and chondroitin sulphate. While the first report of using glucosamine in horses appeared more than 25 years ago, it was not until 1992 that isolated studies began to be reported. Since that time, 15 in vivo papers have been published in the equine literature, usually on products already commercially available and often seeking evidence for efficacy. These studies demonstrate an encouraging trend to manufacturers of these products investing in research, but most do not meet a quality standard that provides sufficient confidence in the results reported. This review discusses the entirety of published in vivo research on glucosamine-based nutraceuticals (GBN) for horses, including that on Cosequin, Cortaflex, Synequin, Sasha's EQ, Myristol, chondroitin sulphate, glucosamine sulphate and glucosamine hydrochloride; and considers experimental limitations of this research along with their impact on interpretation of results. A quality score was calculated for each paper according to preset quality criteria. A minimum quality standard of 60% was set as the threshold for confidence in interpretation of results. Of the 15 papers reviewed, only 3 met the minimum quality standard. Experimental limitations of each research paper are discussed. It is concluded that the quality of studies in this area is generally low, prohibiting meaningful interpretation of the reported results. New high quality research on GBN for horses is needed and recommendations for future research are discussed.
